AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics
Thursday saw a more than 11% increase in Cerevel Therapeutics Holdings (CERE) shares following AbbVie (ABBV)'s agreement to purchase the neuroscience drugmaker for around $8.7 billion. AbbVie will purchase Cerevel for $45 per share as…